Atenolol is a beta-blocker used to manage cardiovascular conditions. This article covers Atenolol, available as a generic medication and marketed under brand names such as Tenormin. It is supplied as a pill in strengths of 25 mg, 50 mg, and 100 mg and is regulated in Hong Kong by the Department of Health’s Drug Office.
Atenolol belongs to the class of cardioselective beta-blockers. It blocks β1-adrenergic receptors primarily found in the heart, reducing the effects of adrenaline and noradrenaline. By doing so, it:
These actions lead to lower cardiac output and a modest reduction in blood pressure. Atenolol’s relatively low lipid solubility limits its penetration into the central nervous system, which contributes to a lower incidence of central side effects compared with non-selective beta-blockers. Oral bioavailability is about 50 %, and the drug reaches peak plasma concentrations within 2-4 hours. Its elimination half-life is roughly 6-9 hours, and it is excreted unchanged primarily by the kidneys.
Atenolol is approved in Hong Kong for the following indications:
These uses are based on extensive clinical data demonstrating that reducing heart rate and myocardial oxygen demand improves outcomes in these conditions. Atenolol is generally prescribed to adults; pediatric use is limited and requires specialist supervision.
Atenolol has been explored in several off-label contexts, though regulatory approval for these uses is lacking. Evidence from peer-reviewed studies suggests possible benefit in:
Disclaimer: Off-label use requires medical supervision and individualized risk assessment.
If any of these serious symptoms occur, seek urgent care.
Major interactions
Calcium channel blockers (e.g., verapamil, diltiazem): additive negative chronotropic effects can cause severe bradycardia.
Digoxin: combined use may increase risk of atrioventricular block.
Moderate interactions
Non-steroidal anti-inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy.
Insulin or oral hypoglycemics: beta-blockade can mask hypoglycemia signs; monitor glucose closely.
CYP enzyme considerations - Atenolol undergoes minimal hepatic metabolism, so clinically significant CYP-mediated interactions are rare.
All doses use the available tablet strengths (25 mg, 50 mg, 100 mg).
Signs of overdose include severe bradycardia, hypotension, and heart block. Emergency treatment involves:
There is no specific antidote for atenolol overdose.
Abrupt cessation is generally safe because atenolol has a moderate half-life, but patients with angina or recent myocardial infarction should be tapered under physician guidance to avoid rebound tachycardia or hypertension.
This article provides educational information about atenolol and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Atenolol’s blood-pressure-lowering effect lasts throughout the day, so many clinicians recommend taking it in the morning to avoid nighttime bradycardia that could disturb sleep. Individual timing should be discussed with a healthcare professional.
Atenolol may lower maximal heart rate, which can alter perceived exertion during vigorous activity. Patients are usually advised to monitor intensity using the Borg Rating of Perceived Exertion rather than heart-rate zones.
Atenolol is relatively hydrophilic, resulting in limited penetration into the central nervous system. Consequently, it has a lower incidence of central side effects such as vivid dreams compared with more lipophilic beta-blockers.
Both contain the same active ingredient, atenolol, and must meet identical regulatory standards for purity, strength, and bioavailability. Inactive ingredients may differ slightly, which can affect tolerability in patients with specific excipient sensitivities.
Atenolol is not commonly associated with cough; the symptom may be unrelated or indicate an underlying respiratory condition. Discuss the cough with a healthcare provider to determine the cause and appropriate management.
Atenolol is classified as a pregnancy-category D drug in many regions due to potential fetal growth restriction. It should be avoided unless the maternal benefit clearly outweighs the fetal risk, and alternative agents are unsuitable.
Some decongestants (e.g., pseudoephedrine) have sympathomimetic activity that can counteract atenolol’s effects and may increase blood pressure. Patients should consult a pharmacist before using such products.
Since atenolol is excreted unchanged by the kidneys, reduced renal clearance can lead to higher plasma levels and increased risk of bradycardia or hypotension. Dose reductions are recommended for patients with significant renal impairment.
Atenolol does not directly alter lipid profiles. However, any medication that changes lifestyle habits (e.g., exercise tolerance) may indirectly influence cholesterol levels.
Key signs include severe dizziness, fainting, heart rate below 40 bpm, very low blood pressure, and difficulty breathing. Immediate medical attention is essential.
